Autres langues Cumberland Pharmaceuticals Inc.

Actions

CPIX

US2307701092

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
7,390 ^USD	-1,60%		-2,89%	+85,68%

04/08	Cumberland Pharmaceuticals Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
04/08	Transcript : Cumberland Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 04, 2026

Autres langues

07/08	Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.
04/08	Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Cumberland: Q2 Earnings Snapshot
04/08	CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
28/07	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
13/07	Cumberland Pharmaceuticals Inc. announces an Equity Buyback for $5 million worth of its shares.
13/07	Cumberland Pharmaceuticals Announces Special Dividend, Payable on July 31, 2026
13/07	Cumberland Declares Special Dividend, Approves $5 Million Share Buyback
13/07	Cumberland Pharmaceuticals : C O R R E C T I O N Cumberland Pharmaceuticals Inc./
13/07	/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
13/07	Cumberland Pharmaceuticals Inc.'s Equity Buyback announced on May 13, 2010, has expired.
13/07	Cumberland Pharmaceuticals Inc. authorizes a Buyback plan.
01/07	Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
01/07	Apotex Inc. completed the acquisition of Certain assets related to certain pharmaceutical products of Cumberland Pharmaceuticals Inc..
26/06	Cumberland Pharmaceuticals Shares Updated Results From Phase 2 FIGHT DMD Trial Evaluating Ifetroban In Duchenne Muscular Dystrophy Heart Disease
26/06	Cumberland Says Updated Data Support Ifetroban in Duchenne Muscular Dystrophy Cardiomyopathy
26/06	Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
19/06	RedHill Biopharma Announces Up To $19.4 Million Private Placement
03/06	RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
02/06	Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study
02/06	Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
02/06	Cumberland Pharmaceuticals and Vanderbilt Health Announce Positive Results from Phase 2A Clinical Trial of Ifetroban for Metastasis Prevention in High-Risk Solid Tumors
28/05	Cumberland Pharmaceuticals Launches Vibativ Injection in China in Strategic Partnership with SciClone Pharmaceuticals Limited
28/05	CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
08/05	Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.